ReviewFrontiers in pharmacology2025
An updated review deciphering the anticancer potential of pentacyclic triterpene lupeol and its nanoformulations.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Lupeol- and Cis-Vaccenic Acid-Containing Bioactive Fraction ofBiomolecules · 2026Article
- Dietary Terpenoids in Advancing Biofilm-Mediated Cancer Prevention: Antibiofilm Cascade, Molecular Crosstalk, and Nano-Facilitated Functional Delivery.Cell biochemistry and function · 2026Review
- Lupeol as a modulator of bacterial resistance mediated by the MepA efflux pump in Staphylococcus aureus.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Molecular Profiling and Selective Pro-Apoptotic Activity of a Pruning-DerivedInternational journal of molecular sciences · 2026Article
- Green chemistry for prostate health: exploring nature's toolbox against cancer, inflammation, and hyperplasia.Molecular diversity · 2026Review
- Pharmacological and Medicinal Properties of the South American Medicinal PlantLife (Basel, Switzerland) · 2026Review
- Anticancer Molecular Mechanisms of Phytosterols: An Updated Review on Clinical Trials.Food science & nutrition · 2026Review
- The phytochemistry and pharmacological activities ofFrontiers in pharmacology · 2026Review
- Phytochemical small molecules fromAmerican journal of translational research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triterpenoids from plants are essential sources of nutraceuticals, which possess numerous positive effects on human health. Lupeol (a pentacyclic dietary triterpenoid) is commonly present in edible fruits, vegetables, and medicinal plants. Numerous investigations on the pharmacological properties of lupeol have been carried out in the past 10 years, and the results have shown that the compound has enormous pharmacological properties, including antioxidant, anti-inflammatory, and anticancer properties. Research has shown that lupeol affects the functioning of numerous molecules, including the cytokines IL-2, NFκB, IL4, IL5, cFLIP, ILβ, and Bcl-2. Our review discusses recent advancements in plant lupeol and its underlying mode of action in combating human carcinoma within the timeframe spanning from 2010 to 2024. Also, we have tried to incorporate recent studies reported till date of the finalization of this review. In order to give researchers the most recent information, highlight the limitations of pertinent research at this time, and highlight both the mechanisms of action of lupeol and recent advances in its formulations that should be strengthened in future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.